Eli Lilly and Company (LLY) - A Comprehensive Overview
Overview:
Eli Lilly and Company, a global pharmaceutical leader, is known for its extensive range of human pharmaceuticals. Founded in 1876 and headquartered in Indianapolis, LLY focuses on discovering, developing, and marketing pharmaceuticals worldwide.
Key Financials:
Stock Performance:
Market Position Against Competitors:
Investor Sentiment:
Conclusion:
Eli Lilly and Company, with its strong financials, diverse product portfolio, and robust operational efficiency, remains a key player in the pharmaceutical industry. While it commands a premium valuation compared to its competitors, its consistent growth in key financial metrics, and innovative product pipeline, position it favorably for future growth. Investors and analysts maintain a cautiously optimistic view of the company's prospects in a competitive market.
Eli Lilly and Company, a global pharmaceutical leader, is known for its extensive range of human pharmaceuticals. Founded in 1876 and headquartered in Indianapolis, LLY focuses on discovering, developing, and marketing pharmaceuticals worldwide.
Key Financials:
- As of December 31, 2022, LLY's total assets stood at $49.49 billion, with a significant portion in current assets ($18.03 billion) and non-current assets ($31.45 billion).
- Net sales/revenue saw a steady increase from $24.55 billion in 2018 to $28.54 billion in 2022.
- Gross profit also rose from $19.59 billion in 2018 to $23.31 billion in 2022.
- Net income displayed notable growth, especially in 2022, with $6.25 billion compared to $3.23 billion in 2018.
- LLY’s operating cash flow improved from $5.53 billion in 2018 to $7.08 billion in 2022.
Stock Performance:
- The stock price as of November 10, 2023, was $597.71, with a 52-week high of $629.97.
- Market Capitalization: $537.5 billion.
- The EPS growth was +14.7% from the prior TTM.
Market Position Against Competitors:
- LLY’s P/E ratio of 83.1 is significantly higher compared to industry peers like Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Merck & Co Inc (MRK), and Bristol-Myers Squibb Co (BMY), indicating a potentially higher growth expectation from the market.
- LLY's Price to Sales ratio is 18.2, showing a premium valuation compared to its competitors.
- Revenue growth at +1.5% is moderate compared to industry growth rates.
Investor Sentiment:
- The Equity Summary Score for LLY is neutral at 6.3, reflecting a balanced view among analysts.
- Analysts’ opinions show a mix of Neutral and Buy, with a significant positive outlook from firms like Jefferies, CSFB, and UBS.
Conclusion:
Eli Lilly and Company, with its strong financials, diverse product portfolio, and robust operational efficiency, remains a key player in the pharmaceutical industry. While it commands a premium valuation compared to its competitors, its consistent growth in key financial metrics, and innovative product pipeline, position it favorably for future growth. Investors and analysts maintain a cautiously optimistic view of the company's prospects in a competitive market.